<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:text="http:///de/fraunhofer/scai/bio/extraction/types/text.ecore" xmlns:container="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/container.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:meta2="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/meta.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:cas="http:///uima/cas.ecore" xmlns:structure="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/structure.ecore" xmlns:image="http:///de/fraunhofer/scai/bio/extraction/types/image.ecore" xmlns:provenance="http:///de/fraunhofer/scai/bio/extraction/types/meta/provenance.ecore" xmlns:meta="http:///de/fraunhofer/scai/bio/extraction/types/meta.ecore" xmlns:documentelement="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <meta:Person xmi:id="8" surname="msood"/>
    <provenance:AgentProvenance xmi:id="13" user="8"/>
    <provenance:ActivityProvenance xmi:id="1" componentId="de.fraunhofer.scai.bio.uima.mysqlreader.ctgov.reader.MySQLReader" startedAtTime="87" endedAtTime="422" version="7.1-SNAPSHOT" parameters="15 19 23 27 31 35 39 43 47 51 55 59 63 67" wasAssociatedWith="13"/>
    <meta:Parameter xmi:id="15" key="condition" value="false" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="19" key="recipient" value="" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="23" key="trackingNr" value="" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="27" key="QueryFile" value="etc/query" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="31" key="Query" value="" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="35" key="connection" value="jdbc:mysql://flux:30008/aetionomy" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="39" key="password" value="Espe52" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="43" key="username" value="root" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="47" key="limit" value="1" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="51" key="offset" value="0" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="55" key="documentCollectionName" value="da520808-d64a-4336-8261-3e397759a010" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="63" key="recipients" value="" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="67" key="event" value="" wasGeneratedBy="1"/>
    <meta:Parameter xmi:id="398" key="inputString" value="" wasGeneratedBy="1"/>
    <meta:KeyValue xmi:id="98" key="license"/>
    <meta:KeyValue xmi:id="414" key="unit" value=""/>
    <meta:KeyValue xmi:id="418" key="tracking-nr" value="da520808-d64a-4336-8261-3e397759a010"/>
    <tcas:DocumentAnnotation xmi:id="109" sofa="102" begin="0" end="10252" language="x-unspecified"/>
    <meta:Header xmi:id="126" sofa="102" begin="0" end="0" source="Huntington Medical Research Institutes" title="Minocycline in Patients With Alzheimer's Disease" authors="152" publicationDate="139" ISSN="NCT01463384" documentConcept="143"/>
    <provenance:EntityProvenance xmi:id="402" documentID="af5fd4814a6a9d0bf62e8ef65be39ae67e67dd7350c13ea2c34120cdc6127a66" userSuppliedID="NCT01463384" wasDerivedFrom="http://www.scai.fraunhofer.de" workflowProvenance="1" wasGeneratedBy="1" wasAttributedTo="13" documentCollectionName="da520808-d64a-4336-8261-3e397759a010" documentURI="file:/home/msood/workspace/MySQLCTgov2XMI/NCT01463384"/>
    <tcas:DocumentAnnotation xmi:id="121" sofa="114" begin="0" end="10252" language="x-unspecified"/>
    <meta2:DocumentTitle xmi:id="162" sofa="114" begin="89" end="177" wasGeneratedBy="1"/>
    <meta2:Abstract xmi:id="170" sofa="114" begin="684" end="1262" wasGeneratedBy="1"/>
    <container:Section xmi:id="176" sofa="114" begin="0" end="669" wasGeneratedBy="1" title="Overview:" rhetorical="Overview:"/>
    <container:Section xmi:id="185" sofa="114" begin="669" end="1264" wasGeneratedBy="1" title="Brief Summary:" rhetorical="Brief Summary:"/>
    <container:Section xmi:id="194" sofa="114" begin="1264" end="3263" wasGeneratedBy="1" title="Detailed Description:" rhetorical="Detailed Description:"/>
    <container:Section xmi:id="203" sofa="114" begin="3263" end="4077" wasGeneratedBy="1" title="Criteria:" rhetorical="Criteria:"/>
    <container:Section xmi:id="230" sofa="114" begin="4077" end="4378" wasGeneratedBy="1" title="Further Study Details:" rhetorical="Further Study Details:"/>
    <container:Section xmi:id="239" sofa="114" begin="4381" end="4615" wasGeneratedBy="1" title="Design Information:" rhetorical="Design Information:"/>
    <container:Section xmi:id="248" sofa="114" begin="4618" end="4759" wasGeneratedBy="1" title="Intervention Information:" rhetorical="Intervention Information:"/>
    <container:Section xmi:id="257" sofa="114" begin="4762" end="7612" wasGeneratedBy="1" title="Outcome Information:" rhetorical="Outcome Information:"/>
    <container:Section xmi:id="275" sofa="114" begin="7616" end="7659" wasGeneratedBy="1" title="Outcome Analysis Details:" rhetorical="Outcome Analysis Details:"/>
    <container:Section xmi:id="284" sofa="114" begin="7663" end="7920" wasGeneratedBy="1" title="Outcome Measure Details:" rhetorical="Outcome Measure Details:"/>
    <container:Section xmi:id="293" sofa="114" begin="7924" end="8080" wasGeneratedBy="1" title="Outcome Values:" rhetorical="Outcome Values:"/>
    <container:Section xmi:id="302" sofa="114" begin="8083" end="8605" wasGeneratedBy="1" title="Study Outcome Details:" rhetorical="Study Outcome Details:"/>
    <container:Section xmi:id="311" sofa="114" begin="8608" end="8788" wasGeneratedBy="1" title="Location Details:" rhetorical="Location Details:"/>
    <container:Section xmi:id="338" sofa="114" begin="8791" end="9764" wasGeneratedBy="1" title="Arm Group Details:" rhetorical="Arm Group Details:"/>
    <container:Section xmi:id="374" sofa="114" begin="9767" end="10222" wasGeneratedBy="1" title="Baseline Information:" rhetorical="Baseline Information:"/>
    <container:SubSection xmi:id="212" sofa="114" begin="3273" end="3474" wasGeneratedBy="1" title="Inclusion Criteria." rhetorical="Inclusion Criteria."/>
    <container:SubSection xmi:id="221" sofa="114" begin="3474" end="4077" wasGeneratedBy="1" title="Exclusion Criteria." rhetorical="Exclusion Criteria."/>
    <container:SubSection xmi:id="266" sofa="114" begin="4787" end="7612" wasGeneratedBy="1" title="Outcome Details:" rhetorical="Outcome Details:"/>
    <container:SubSection xmi:id="320" sofa="114" begin="8630" end="8741" wasGeneratedBy="1" title="Facility Details:" rhetorical="Facility Details:"/>
    <container:SubSection xmi:id="329" sofa="114" begin="8745" end="8788" wasGeneratedBy="1" title="Facility Contact Details:" rhetorical="Facility Contact Details:"/>
    <container:SubSection xmi:id="347" sofa="114" begin="9793" end="9812" wasGeneratedBy="1" title="Baseline ID:" rhetorical="Baseline ID:"/>
    <container:SubSection xmi:id="356" sofa="114" begin="9816" end="9858" wasGeneratedBy="1" title="Baseline Measure Details:" rhetorical="Baseline Measure Details:"/>
    <container:SubSection xmi:id="365" sofa="114" begin="9862" end="10222" wasGeneratedBy="1" title="Baseline Measure Cateogary Details:" rhetorical="Baseline Measure Cateogary Details:"/>
    <meta2:Reference xmi:id="383" sofa="114" begin="4314" end="4328" wasGeneratedBy="1"/>
    <cas:Sofa xmi:id="102" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="Overview:&#9;&#10;Brief Title:&#9;Minocycline in Patients With Alzheimer's Disease&#10;Official Title:&#9;MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy&#10;NCT-ID:&#9;NCT01463384&#10;Start Date:&#9;September 2011&#10;Completion Date:&#9;October 2012&#10;First Received Date:&#9;October 25, 2011&#10;Last Updated:&#9;September 23, 2014&#10;Verification Date:&#9;September 2014&#10;Authority:&#9;United States: Institutional Review Board&#10;Condition:&#9;Mild Cognitive Impairment;;Alzheimer's Disease&#10;Keyword:&#9;Magnetic Resonance Imaging;;Magnetic Resonance Spectroscopy;;Neuroinflammation;;Mild Cognitive Impairment;;Alzheimer's Disease;;Minocycline&#10;URL:&#9;http://clinicaltrials.gov/show/NCT01463384&#10;&#10;Brief Summary:&#9;Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance imaging (MRI) and proton (1H ) and carbon 13 (13C) magnetic resonance spectroscopy (MRS). Each individual will receive minocycline oral administration for 4 weeks initially, after which MRI, MRS and neuropsychological results will be recorded. If no adverse side effects occur, subjects will continue minocycline administration for an additional 5 months.&#10;&#10;Detailed Description:&#9;In the course of on-going trials of novel MRI procedures for Neurological Diagnosis, the investigators have established non-invasive BIOMARKERS (Note: Biomarkers are objective Laboratory tests used in, but not replacing Clinical diagnostic criteria of any disease,in this case age-related dementia of the Alzheimer type and its pre-clinical forms including Mild Cognitive Impairment - MCI) which significantly assist in the Diagnosis of Alzheimer's Disease. MRS, rather like blood tests which are applied for screening and exclusion of medical disorders, provides a pattern of brain chemicals from which this and many other diagnoses have become available (see: Magnetic Resonance Spectroscopy in Neurological Diagnosis: E.R Danielsen and B.D. Ross, Marcel Dekker New York, 1999). Diagnosis of Alzheimer's Disease has hitherto been exclusively a clinical diagnosis, made on the basis of non-specific tests by the treating physician/neurologist. Furthermore, treatments have been of limited efficacy so that the pressure for conclusive diagnosis or an objective characterization of disease progression (or better, regression) has not been a priority. This conservative approach to Alzheimer's Disease changed in 2010 with the Report of National Institutes of Aging. First: The failures of treatment have been ascribed to introduction only in patients with advanced disease (&quot;dementia&quot;). Second: A preliminary form of AD, known as pre-clinical or Mild Cognitive Impairment, has been recognized, distinct from, and generally earlier in the disease course. Third: A new set of diagnostic criteria, which include objective 'biomarkers', from cerebrospinal fluid, genetic and imaging analyzes, has been accepted by the Expert Panel. Finally, Clinical trials of existing and new drugs for Alzheimer's Disease are expected to yield better results if initiated earlier - in the pre-clinical phase - and the outcomes evaluated by the earlier changes in an approved panel of biomarkers.&#10;&#10;Criteria:&#9;Inclusion Criteria.&#10; - Cognitively normal elderly subjects between the ages of 55-90 and patients aged 55 - 90 years who have mild cognitive impairment (MCI) or clinically defined Alzheimer's disease. Exclusion Criteria.&#10; - Any person with medical devices such as cardiac pacemakers/defibrillators or neuro-implants as they are contra-indications for MRI/MRS exam.&#10; - Since the effects of MRI are unknown to the fetus or unborn child, any person who is or may be pregnant will be excluded from the study.&#10; - History of known allergy or intolerance to minocycline or any other tetracycline - Impaired renal function (plasma Creatinine) or blood urea nitrogen (BUN) levels exceeds twice normal upper limit which can result in higher serum levels of tetracycline, azotemia, hyperphosphatemia and acidosis.&#10;&#10;Further Study Details:&#9;&#10;Overall Status:&#9;Completed&#10;Phase:&#9;Phase 2&#10;Study Type:&#9;Interventional&#10;Healthy Volunteer:&#9;Accepts Healthy Volunteers&#10;Enrollment:&#9;13&#10;Gender:&#9;Both&#10;Minimum Age:&#9;55 Years&#10;Maximum Age:&#9;90 Years&#10;&#10;Other ID's:&#9;Secondary ID: No information,Org Study ID: LKW-AB34&#10;PubMedID:&#9;No information&#10;&#10;1. Design Information:&#9;DesignName:EndpointClassification,DesignValue:EfficacyStudy.DesignName:InterventionModel,DesignValue:SingleGroupAssignment.DesignName:Masking,DesignValue:OpenLabel.DesignName:PrimaryPurpose,DesignValue:Treatment.&#10;&#10;2. Intervention Information:&#10;&#9;Intervention Type: Drug,Intervention Name: Minocycline,Intervention Description: 50mg, twice daily for 6 months.&#10;&#10;3. Outcome Information:&#10;3.1 Outcome Details:&#10;&#9;Outcome Type: Primary.&#10;Outcome Title: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: RBANS is a brief neurocognitive battery with four alternate forms, measuring immediate and delayed memory, attention, language, and visuospatial skills. RBANS was developed as a stand-alone â€œcoreâ€� battery for the detection and neurocognitive characterization of dementia and as a brief neurocognitive battery for the detection and tracking of neurocognitive deficits in a variety of disorders. (Reference: http://rbans.com/) Qualitative Description of Index Scores: Index Score Classification 130 and above Very Superior 120-129 Superior 110-119 High Average 90-109 Average 80-89 Low Average 70-79 Borderline 69 and below Extremely Low Psychometric range for RBANS: AD 0 - 77 MCI 78 - 99 Normal &gt; 100 Range of scores: Minimum = 0, Maximum = 130 Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. &#10;&#10;Outcome Type: Primary.&#10;Outcome Title: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)..&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: Using magnetic resonance images acquired, hippocampal volume was measured monthly for 6 months. Normal range for hippocampal volume in aged-matched controls is 6.6 - 8.8 cm^3. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. &#10;&#10;Outcome Type: Primary.&#10;Outcome Title: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: It has been demonstrated in numerous studies over the past decade that magnetic resonance spectroscopy (MRS) can be used for the diagnosis of Alzheimerâ€™s disease. By measuring an area within the posterior cingulate gyrus, one can obtain a biochemical signature of that region in AD whereby NAA is reduced and mI is increased. These two biomarkers, N-acetylaspartate (NAA, a neuronal marker) and myo-inositol (mI, a glial marker) were quantified and then used to calculate NAA/mI (an index currently widely used for AD and MCI diagnosis). Scale of MRS biomarkers for aged-matched controls: NAA = 1.43, mI = 0.60, NAA/mI = 2.38. Any value lower than NAA/mI of 2.38 are considered not normal. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration.&#10;&#10;&#10;3.2 Outcome Analysis Details:&#10;&#9;No information.&#10;3.3 Outcome Measure Details:&#10;&#9;Outcome Units of Measure: Ratio,Measure Type: Mean .&#10;Outcome Units of Measure: cm^3,Measure Type: Mean .&#10;Outcome Units of Measure: units on a scale,Measure Type: Mean .&#10;Outcome Units of Measure: participants,Measure Type: Number.&#10;&#10;3.4 Outcome Values:&#10;&#9;1,8,4,32.5,32.9,81,58.7,63.8,106,108.4,123.6,49,5.49,5.42,4.94,6.35,6.30,7.60,6.98,6.92,6.82,2.44,2.47,1.69,1.78,1.84,1.87,1.80,2.08,2.42&#10;&#10;4. Study Outcome Details:&#10;&#9;Study Outcome Type:  primary outcome,Measure: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) .&#10;Study Outcome Type:  primary outcome,Measure: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC). .&#10;Study Outcome Type:  primary outcome,Measure: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).&#10;&#10;&#10;5. Location Details:&#10;5.1 Facility Details:&#9;City: Pasadena,Country: United States,Facility Name: Huntington Medical Research Institutes.&#10;5.2 Facility Contact Details:&#9;No information.&#10;&#10;6. Arm Group Details:&#10;&#9;Arm Group Label:  Minocycline,Arm Group Type: Active Comparator,Arm Group DEscription: Subjects will be administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline,Arm Group Type: Baseline,Arm Group DEscription: Subjects administered 50mg minocycline twice daily for 6 months .&#10;Arm Group Label:  Minocycline,Arm Group Type: Participant Flow,Arm Group DEscription: Subjects were administered 50mg minocycline twice daily for 6 months .&#10;Arm Group Label:  Minocycline MCI,Arm Group Type: Results Outcome,Arm Group DEscription: Mild cognitively impaired subject who was administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline AD,Arm Group Type: Results Outcome,Arm Group DEscription: Alzheimer subjects who were administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline NC,Arm Group Type: Results Outcome,Arm Group DEscription: Normal control subjects who were administered 50mg minocycline twice daily.&#10;&#10;&#10;7. Baseline Information:&#10;7.1 Baseline ID:&#9;13745&#10;7.2 Baseline Measure Details:&#9;No information.&#10;7.3 Baseline Measure Cateogary Details:&#9;Cateogary Title:  Female,Baseline Value: 308 .&#10;Cateogary Title:  Male,Baseline Value: 433 .&#10;Cateogary Title:  Female,Baseline Value: 178 .&#10;Cateogary Title:  Male,Baseline Value: 191 .&#10;Cateogary Title:  Female,Baseline Value: 190 .&#10;Cateogary Title:  Female,Baseline Value: 676 .&#10;Cateogary Title:  Male,Baseline Value: 815.&#10;&#10;&#10;8. Reference:&#10;&#9;No information&#10;"/>
    <cas:Sofa xmi:id="114" sofaNum="2" sofaID="DocumentView" mimeType="text" sofaString="Overview:&#9;&#10;Brief Title:&#9;Minocycline in Patients With Alzheimer's Disease&#10;Official Title:&#9;MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy&#10;NCT-ID:&#9;NCT01463384&#10;Start Date:&#9;September 2011&#10;Completion Date:&#9;October 2012&#10;First Received Date:&#9;October 25, 2011&#10;Last Updated:&#9;September 23, 2014&#10;Verification Date:&#9;September 2014&#10;Authority:&#9;United States: Institutional Review Board&#10;Condition:&#9;Mild Cognitive Impairment;;Alzheimer's Disease&#10;Keyword:&#9;Magnetic Resonance Imaging;;Magnetic Resonance Spectroscopy;;Neuroinflammation;;Mild Cognitive Impairment;;Alzheimer's Disease;;Minocycline&#10;URL:&#9;http://clinicaltrials.gov/show/NCT01463384&#10;&#10;Brief Summary:&#9;Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance imaging (MRI) and proton (1H ) and carbon 13 (13C) magnetic resonance spectroscopy (MRS). Each individual will receive minocycline oral administration for 4 weeks initially, after which MRI, MRS and neuropsychological results will be recorded. If no adverse side effects occur, subjects will continue minocycline administration for an additional 5 months.&#10;&#10;Detailed Description:&#9;In the course of on-going trials of novel MRI procedures for Neurological Diagnosis, the investigators have established non-invasive BIOMARKERS (Note: Biomarkers are objective Laboratory tests used in, but not replacing Clinical diagnostic criteria of any disease,in this case age-related dementia of the Alzheimer type and its pre-clinical forms including Mild Cognitive Impairment - MCI) which significantly assist in the Diagnosis of Alzheimer's Disease. MRS, rather like blood tests which are applied for screening and exclusion of medical disorders, provides a pattern of brain chemicals from which this and many other diagnoses have become available (see: Magnetic Resonance Spectroscopy in Neurological Diagnosis: E.R Danielsen and B.D. Ross, Marcel Dekker New York, 1999). Diagnosis of Alzheimer's Disease has hitherto been exclusively a clinical diagnosis, made on the basis of non-specific tests by the treating physician/neurologist. Furthermore, treatments have been of limited efficacy so that the pressure for conclusive diagnosis or an objective characterization of disease progression (or better, regression) has not been a priority. This conservative approach to Alzheimer's Disease changed in 2010 with the Report of National Institutes of Aging. First: The failures of treatment have been ascribed to introduction only in patients with advanced disease (&quot;dementia&quot;). Second: A preliminary form of AD, known as pre-clinical or Mild Cognitive Impairment, has been recognized, distinct from, and generally earlier in the disease course. Third: A new set of diagnostic criteria, which include objective 'biomarkers', from cerebrospinal fluid, genetic and imaging analyzes, has been accepted by the Expert Panel. Finally, Clinical trials of existing and new drugs for Alzheimer's Disease are expected to yield better results if initiated earlier - in the pre-clinical phase - and the outcomes evaluated by the earlier changes in an approved panel of biomarkers.&#10;&#10;Criteria:&#9;Inclusion Criteria.&#10; - Cognitively normal elderly subjects between the ages of 55-90 and patients aged 55 - 90 years who have mild cognitive impairment (MCI) or clinically defined Alzheimer's disease. Exclusion Criteria.&#10; - Any person with medical devices such as cardiac pacemakers/defibrillators or neuro-implants as they are contra-indications for MRI/MRS exam.&#10; - Since the effects of MRI are unknown to the fetus or unborn child, any person who is or may be pregnant will be excluded from the study.&#10; - History of known allergy or intolerance to minocycline or any other tetracycline - Impaired renal function (plasma Creatinine) or blood urea nitrogen (BUN) levels exceeds twice normal upper limit which can result in higher serum levels of tetracycline, azotemia, hyperphosphatemia and acidosis.&#10;&#10;Further Study Details:&#9;&#10;Overall Status:&#9;Completed&#10;Phase:&#9;Phase 2&#10;Study Type:&#9;Interventional&#10;Healthy Volunteer:&#9;Accepts Healthy Volunteers&#10;Enrollment:&#9;13&#10;Gender:&#9;Both&#10;Minimum Age:&#9;55 Years&#10;Maximum Age:&#9;90 Years&#10;&#10;Other ID's:&#9;Secondary ID: No information,Org Study ID: LKW-AB34&#10;PubMedID:&#9;No information&#10;&#10;1. Design Information:&#9;DesignName:EndpointClassification,DesignValue:EfficacyStudy.DesignName:InterventionModel,DesignValue:SingleGroupAssignment.DesignName:Masking,DesignValue:OpenLabel.DesignName:PrimaryPurpose,DesignValue:Treatment.&#10;&#10;2. Intervention Information:&#10;&#9;Intervention Type: Drug,Intervention Name: Minocycline,Intervention Description: 50mg, twice daily for 6 months.&#10;&#10;3. Outcome Information:&#10;3.1 Outcome Details:&#10;&#9;Outcome Type: Primary.&#10;Outcome Title: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: RBANS is a brief neurocognitive battery with four alternate forms, measuring immediate and delayed memory, attention, language, and visuospatial skills. RBANS was developed as a stand-alone â€œcoreâ€� battery for the detection and neurocognitive characterization of dementia and as a brief neurocognitive battery for the detection and tracking of neurocognitive deficits in a variety of disorders. (Reference: http://rbans.com/) Qualitative Description of Index Scores: Index Score Classification 130 and above Very Superior 120-129 Superior 110-119 High Average 90-109 Average 80-89 Low Average 70-79 Borderline 69 and below Extremely Low Psychometric range for RBANS: AD 0 - 77 MCI 78 - 99 Normal &gt; 100 Range of scores: Minimum = 0, Maximum = 130 Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. &#10;&#10;Outcome Type: Primary.&#10;Outcome Title: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)..&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: Using magnetic resonance images acquired, hippocampal volume was measured monthly for 6 months. Normal range for hippocampal volume in aged-matched controls is 6.6 - 8.8 cm^3. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. &#10;&#10;Outcome Type: Primary.&#10;Outcome Title: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: It has been demonstrated in numerous studies over the past decade that magnetic resonance spectroscopy (MRS) can be used for the diagnosis of Alzheimerâ€™s disease. By measuring an area within the posterior cingulate gyrus, one can obtain a biochemical signature of that region in AD whereby NAA is reduced and mI is increased. These two biomarkers, N-acetylaspartate (NAA, a neuronal marker) and myo-inositol (mI, a glial marker) were quantified and then used to calculate NAA/mI (an index currently widely used for AD and MCI diagnosis). Scale of MRS biomarkers for aged-matched controls: NAA = 1.43, mI = 0.60, NAA/mI = 2.38. Any value lower than NAA/mI of 2.38 are considered not normal. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration.&#10;&#10;&#10;3.2 Outcome Analysis Details:&#10;&#9;No information.&#10;3.3 Outcome Measure Details:&#10;&#9;Outcome Units of Measure: Ratio,Measure Type: Mean .&#10;Outcome Units of Measure: cm^3,Measure Type: Mean .&#10;Outcome Units of Measure: units on a scale,Measure Type: Mean .&#10;Outcome Units of Measure: participants,Measure Type: Number.&#10;&#10;3.4 Outcome Values:&#10;&#9;1,8,4,32.5,32.9,81,58.7,63.8,106,108.4,123.6,49,5.49,5.42,4.94,6.35,6.30,7.60,6.98,6.92,6.82,2.44,2.47,1.69,1.78,1.84,1.87,1.80,2.08,2.42&#10;&#10;4. Study Outcome Details:&#10;&#9;Study Outcome Type:  primary outcome,Measure: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) .&#10;Study Outcome Type:  primary outcome,Measure: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC). .&#10;Study Outcome Type:  primary outcome,Measure: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).&#10;&#10;&#10;5. Location Details:&#10;5.1 Facility Details:&#9;City: Pasadena,Country: United States,Facility Name: Huntington Medical Research Institutes.&#10;5.2 Facility Contact Details:&#9;No information.&#10;&#10;6. Arm Group Details:&#10;&#9;Arm Group Label:  Minocycline,Arm Group Type: Active Comparator,Arm Group DEscription: Subjects will be administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline,Arm Group Type: Baseline,Arm Group DEscription: Subjects administered 50mg minocycline twice daily for 6 months .&#10;Arm Group Label:  Minocycline,Arm Group Type: Participant Flow,Arm Group DEscription: Subjects were administered 50mg minocycline twice daily for 6 months .&#10;Arm Group Label:  Minocycline MCI,Arm Group Type: Results Outcome,Arm Group DEscription: Mild cognitively impaired subject who was administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline AD,Arm Group Type: Results Outcome,Arm Group DEscription: Alzheimer subjects who were administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline NC,Arm Group Type: Results Outcome,Arm Group DEscription: Normal control subjects who were administered 50mg minocycline twice daily.&#10;&#10;&#10;7. Baseline Information:&#10;7.1 Baseline ID:&#9;13745&#10;7.2 Baseline Measure Details:&#9;No information.&#10;7.3 Baseline Measure Cateogary Details:&#9;Cateogary Title:  Female,Baseline Value: 308 .&#10;Cateogary Title:  Male,Baseline Value: 433 .&#10;Cateogary Title:  Female,Baseline Value: 178 .&#10;Cateogary Title:  Male,Baseline Value: 191 .&#10;Cateogary Title:  Female,Baseline Value: 190 .&#10;Cateogary Title:  Female,Baseline Value: 676 .&#10;Cateogary Title:  Male,Baseline Value: 815.&#10;&#10;&#10;8. Reference:&#10;&#9;No information&#10;"/>
    <meta:DateTime xmi:id="87" day="28" month="5" year="2016" hour="13" minute="53" second="59"/>
    <meta:DateTime xmi:id="422" day="28" month="5" year="2016" hour="13" minute="53" second="59"/>
    <meta:Parameter xmi:id="59" key="license" value="" wasGeneratedBy="1"/>
    <meta:Person xmi:id="152" surname="" forename=""/>
    <meta:Date xmi:id="139" day="25" month="10" year="2011"/>
    <meta:Concept xmi:id="143" prefLabel="149" identifier="NCT01463384" identifierSource="clinicaltrials.gov"/>
    <meta:Label xmi:id="149" value="ctgov:NCT01463384"/>
    <cas:View sofa="102" members="8 13 1 15 19 23 27 31 35 39 43 47 51 55 63 67 398 98 414 418 109 126 402"/>
    <cas:View sofa="114" members="121 162 170 176 185 194 203 230 239 248 257 275 284 293 302 311 338 374 212 221 266 320 329 347 356 365 383"/>
</xmi:XMI>
